The neutrophil to lymphocyte and platelet to lymphocyte ratios as biomarkers for lung cancer development

Lung Cancer

Volumn 97, Issue , 2016, Pages 28-34

  Sanchez Salcedo, Pablo ^a   de Torres, Juan P ^a   Martinez Urbistondo, Diego ^a   Gonzalez Gutierrez, Jessica ^a   Berto, Juan ^a   Campo, Arantzazu ^a   Alcaide, Ana B ^a   Zulueta, Javier J ^a  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

Emphysema; Lung cancer; Lung cancer screening; Neutrophil to lymphocyte ratio; NLR; Platelet to lymphocyte ratio; PLR

Indexed keywords

BIOLOGICAL MARKER;

ADULT; ARTICLE; BLOOD CELL COUNT; CANCER INCIDENCE; CANCER PROGNOSIS; CANCER RISK; CONTROLLED STUDY; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; LUNG CANCER; LUNG EMPHYSEMA; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NEUTROPHIL LYMPHOCYTE RATIO; NON SMALL CELL LUNG CANCER; PLATELET LYMPHOCYTE RATIO; PRIORITY JOURNAL; AGED; CHRONIC OBSTRUCTIVE LUNG DISEASE; DIAGNOSTIC IMAGING; EARLY CANCER DIAGNOSIS; EMPHYSEMA; IMMUNOLOGY; INCIDENCE; LUNG NEOPLASMS; LYMPHOCYTE COUNT; NEUTROPHIL; PATHOLOGY; PREDICTIVE VALUE; PREVALENCE; PROCEDURES; RISK ASSESSMENT; SPIROMETRY; THROMBOCYTE COUNT; X-RAY COMPUTED TOMOGRAPHY;

AGED; BIOMARKERS; EARLY DETECTION OF CANCER; EMPHYSEMA; FEMALE; HUMANS; INCIDENCE; LUNG NEOPLASMS; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; NEUTROPHILS; PLATELET COUNT; PREDICTIVE VALUE OF TESTS; PREVALENCE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK ASSESSMENT; SPIROMETRY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84963940284     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2016.04.010     Document Type: Article

References (39)

1. Templeton A.J., McNamara M.G., Šeruga B., Vera-Badillo F.E., Aneja P., Ocaña A., et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J. Natl. Cancer Inst. 2014, 106. (dju124). 10.1093/jnci/dju124.
2. Templeton A.J., Ace O., McNamara M.G., Al-Mubarak M., Vera-Badillo F.E., Hermanns T., et al. Prognostic role of platelet to lymphocyte ratio in solid tumors: a systematic review and meta-analysis. Cancer Epidemiol. Biomark. Prev. 2014, 23:1204-1212. 10.1158/1055-9965.EPI-14-0146.
3. Zhou X., Du Y., Huang Z., Xu J., Qiu T., Wang J., et al. Prognostic value of PLR in various cancers: a meta-analysis. PLoS One 2014, 9:e101119. 10.1371/journal.pone.0101119.
4. Shah N., Parikh V., Patel N., Patel N., Badheka A., Deshmukh A., et al. Neutrophil lymphocyte ratio significantly improves the Framingham risk score in prediction of coronary heart disease mortality: insights from the National Health and Nutrition Examination Survey-III. Int. J. Cardiol. 2014, 171:390-397. 10.1016/j.ijcard.2013.12.019.
5. Günay E., Sarinç Ulaşli S., Akar O., Ahsen A., Günay S., Koyuncu T., et al. Neutrophil-to-lymphocyte ratio in chronic obstructive pulmonary disease: a retrospective study. Inflammation 2014, 37:374-380. 10.1007/s10753-013-9749-1.
6. Turkmen K., Tonbul H.Z., Toker A., Gaipov A., Erdur F.M., Cicekler H., et al. The relationship between oxidative stress, inflammation, and atherosclerosis in renal transplant and end-stage renal disease patients. Ren. Fail. 2012, 34:1229-1237. 10.3109/0886022X.2012.723580.
7. Uslu A.U., Küçük A., Şahin A., Ugan Y., Yilmaz R., Güngör T., et al. Two new inflammatory markers associated with disease activity score-28 in patients with rheumatoid arthritis: neutrophil-lymphocyte ratio and platelet-lymphocyte ratio. Int. J. Rheum. Dis. 2015, 10.1111/1756-185x.12582.
8. Guthrie G.J.K., Charles K.A., Roxburgh C.S.D., Horgan P.G., McMillan D.C., Clarke S.J. The systemic inflammation-based neutrophil-lymphocyte ratio: experience in patients with cancer. Crit. Rev. Oncol. Hematol. 2013, 88:218-230. 10.1016/j.critrevonc.2013.03.010.
9. Zhang H., Zhang L., Zhu K., Shi B., Yin Y., Zhu J., et al. Prognostic significance of combination of preoperative platelet count and neutrophil-lymphocyte ratio (COP-NLR) in patients with non-Small cell lung cancer: based on a large cohort study. PLoS One 2015, 10:e0126496. 10.1371/journal.pone.0126496.
10. Cannon N.A., Meyer J., Iyengar P., Ahn C., Westover K.D., Choy H., et al. Neutrophil-lymphocyte and platelet-lymphocyte ratios as prognostic factors after stereotactic radiation therapy for early-stage non-small-cell lung cancer. J. Thorac. Oncol. 2015, 10:280-285. 10.1097/JTO.0000000000000399.
11. Unal D., Eroglu C., Kurtul N., Oguz A., Tasdemir A. Are neutrophil/lymphocyte and platelet/lymphocyte rates in patients with non-small cell lung cancer associated with treatment response and prognosis?. Asian Pac. J. Cancer Prev. 2013, 14:5237-5242. (accessed 11.05.15). http://www.ncbi.nlm.nih.gov/pubmed/24175807.
12. Kang M.H., Go S.-I., Song H.-N., Lee A., Kim S.-H., Kang J.-H., et al. The prognostic impact of the neutrophil-to-lymphocyte ratio in patients with small-cell lung cancer. Br. J. Cancer 2014, 111:452-460. 10.1038/bjc.2014.317.
13. Lin G.-N., Peng J.-W., Liu P.-P., Liu D.-Y., Xiao J.-J., Chen X.-Q. Elevated neutrophil-to-lymphocyte ratio predicts poor outcome in patients with advanced non-small-cell lung cancer receiving first-line gefitinib or erlotinib treatment. Asia. Pac. J. Clin. Oncol. 2014, 10.1111/ajco.12273.
14. Sanchez-Salcedo P., Berto J., De-Torres J.P., Campo A., Alcaide A.B., Bastarrika G., et al. Lung cancer screening: fourteen year experience of the pamplona early detection program (P-IELCAP). Arch. Bronconeumol. 2015, 51:169-176. 10.1016/j.arbr.2015.02.015.
15. Henschke C.I., Yankelevitz D.F., Libby D.M., Pasmantier M.W., Smith J.P., Miettinen O.S. Survival of patients with stage I lung cancer detected on CT screening. N. Engl. J. Med. 2006, 355:1763-1771. 10.1056/NEJMoa060476.
16. International Early Lung Cancer Action Program protocol (accessed 17.10.13) at)., (n.d.). http://www.IELCAP.org.
17. Bastarrika G., Wisnivesky J.P., Pueyo J.C., Díaz L., Arraiza M., Villanueva A., et al. Low-dose volumetric computed tomography for quantification of emphysema in asymptomatic smokers participating in an early lung cancer detection trial. J. Thorac. Imaging 2009, 24:206-211. 10.1097/RTI.0b013e3181a65263.
18. Vestbo J., Hurd S.S., Agustí A.G., Jones P.W., Vogelmeier C., Anzueto A., et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am. J. Respir. Crit. Care Med. 2013, 187:347-365. 10.1164/rccm.201204-0596PP.
19. Kos M., Hocazade C., Kos F.T., Uncu D., Karakas E., Dogan M., et al. Prognostic role of pretreatment platelet/lymphocyte ratio in patients with non-small cell lung cancer. Wien. Klin. Wochenschr. 2015, 10.1007/s00508-015-0724-8.
20. Lee Y., Kim S.H., Han J.Y., Kim H.T., Yun T., Lee J.S. Early neutrophil-to-lymphocyte ratio reduction as a surrogate marker of prognosis in never smokers with advanced lung adenocarcinoma receiving gefitinib or standard chemotherapy as first-line therapy. J. Cancer Res. Clin. Oncol. 2012, 138:2009-2016. 10.1007/s00432-012-1281-4.
21. Miyazaki T., Yamasaki N., Tsuchiya T., Matsumoto K., Kunizaki M., Taniguchi D., et al. Inflammation-based scoring is a useful prognostic predictor of pulmonary resection for elderly patients with clinical stage I non-small-cell lung cancer. Eur. J. Cardio-Thorac. Surg. 2014, 10.1093/ejcts/ezu514.
22. Moyer V.A. Screening for lung cancer: U.S preventive services task force recommendation statement. Ann. Intern. Med. 2014, 160:330-338. 10.7326/M13-2771.
23. Kauczor H.-U., Bonomo L., Gaga M., Nackaerts K., Peled N., Prokop M., et al. ESR/ERS white paper on lung cancer screening. Eur. Respir. J. 2015, 1-12. 10.1183/09031936.00033015.
24. Tammemägi M.C., Katki H.A., Hocking W.G., Church T.R., Caporaso N., Kvale P.A., et al. Selection criteria for lung-cancer screening. N. Engl. J. Med. 2013, 368:728-736. 10.1056/NEJMoa1211776.
25. Casanova C., Aguirre-Jaime A., de Torres J.P., Pinto-Plata V., Baz R., Marin J.M., et al. Longitudinal assessment in COPD patients: multidimensional variability and outcomes. Eur. Respir. J. 2014, 43:745-753. 10.1183/09031936.00096913.
26. Wang M.L., Gunel E., Petsonk E.L. Design strategies for longitudinal spirometry studies: study duration and measurement frequency. Am. J. Respir. Crit. Care Med. 2000, 162:2134-2138. (accessed 14.12.12). http://www.ncbi.nlm.nih.gov/pubmed/11112127.
27. Slatore C.G., Horeweg N., Jett J.R., Midthun D.E., Powell C.A., Wiener R.S., et al. An official american thoracic society research statement: a research framework for pulmonary nodule evaluation and management. Am. J. Respir. Crit. Care Med. 2015, 192:500-514. 10.1164/rccm.201506-1082ST.
28. de Torres J.P., Bastarrika G., Wisnivesky J.P., Alcaide A.B., Campo A., Seijo L.M., et al. Assessing the relationship between lung cancer risk and emphysema detected on low-dose CT of the chest. Chest 2007, 132:1932-1938. 10.1378/chest.07-1490.
29. Sanchez-Salcedo P., Wilson D.O., De-Torres J.P., Weissfeld J.L., Berto J., Campo A., et al. Improving selection criteria for lung cancer screening: the potential role of emphysema. Am. J. Respir. Crit. Care Med. 2015, 191:924-931. 10.1164/rccm.201410-1848OC.
30. Lippitz B.E. Cytokine patterns in patients with cancer: a systematic review. Lancet Oncol. 2013, 14:218-228. 10.1016/S1470-2045(12)70582-X.
31. Karachaliou N., Pilotto S., Bria E., Rosell R. Platelets and their role in cancer evolution and immune system. Transl. Lung Cancer Res. 2015, 4:713-720. 10.3978/j.issn.2218-6751.2015.10.09.
32. Dunn G.P., Old L.J., Schreiber R.D. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 2004, 21:137-148. 10.1016/j.immuni.2004.07.017.
33. Nilsson R.J.A., Balaj L., Hulleman E., van Rijn S., Pegtel D.M., Walraven M., et al. Blood platelets contain tumor-derived RNA biomarkers. Blood 2011, 118:3680-3683. 10.1182/blood-2011-03-344408.
34. Mishalian I., Granot Z., Fridlender Z.G. The diversity of circulating neutrophils in cancer. Immunobiology 2016, 10.1016/j.imbio.2016.02.001.
35. Li J., Chen Q., Luo X., Hong J., Pan K., Lin X., et al. Neutrophil-to-Lymphocyte ratio positively correlates to age in healthy population. J. Clin. Lab. Anal. 2014, 1-7. 10.1002/jcla.21791.
36. Thomsen M., Ingebrigtsen T.S., Marott J.L., Dahl M., Lange P., Vestbo J., et al. Inflammatory biomarkers and exacerbations in chronic obstructive pulmonary disease. JAMA 2013, 309:2353-2361. 10.1001/jama.2013.5732.
37. Gan W.Q., Man S.F.P., Senthilselvan A., Sin D.D. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax 2004, 59:574-580. (accessed 21.01.14). http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1747070%26tool=pmcentrez%26rendertype=abstract.
38. Omori H., Tsuji M., Sata K., Iyonaga C., Narimatsu A., Mihara S., et al. Correlation of C-reactive protein with disease severity in CT diagnosed emphysema. Respirology 2009, 14:551-558. 10.1111/j.1440-1843.2009.01519.x.
39. de-Torres J.P., Blanco D., Alcaide A.B., Seijo L.M., Bastarrika G., Pajares M.J., et al. Smokers with CT detected emphysema and No airway obstruction have decreased plasma levels of EGF, IL-15, IL-8 and IL-1ra. PLoS One 2013, 8. 10.1371/journal.pone.0060260.